Bio-Path Holdings, Inc. (BPTH)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.84 Million USD | -13.97% |
| 2022 | -13.9 Million USD | -33.11% |
| 2021 | -10.44 Million USD | 4.26% |
| 2020 | -10.9 Million USD | -25.48% |
| 2019 | -8.69 Million USD | -1.2% |
| 2018 | -8.59 Million USD | 4.19% |
| 2017 | -8.96 Million USD | -5.79% |
| 2016 | -8.47 Million USD | -54.53% |
| 2015 | -5.48 Million USD | -20.74% |
| 2014 | -4.54 Million USD | -38.94% |
| 2013 | -3.26 Million USD | -26.58% |
| 2012 | -2.58 Million USD | -9.18% |
| 2011 | -2.36 Million USD | -1.68% |
| 2010 | -2.32 Million USD | -17.91% |
| 2009 | -1.97 Million USD | 31.82% |
| 2008 | -2.89 Million USD | -2552.14% |
| 2007 | -109.11 Thousand USD | 19.34% |
| 2006 | -135.26 Thousand USD | -102.04% |
| 2005 | -66.95 Thousand USD | -23.38% |
| 2004 | -54.26 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.03 Million USD | 17.78% |
| 2024 Q1 | -3.69 Million USD | -21.83% |
| 2023 Q2 | -4.24 Million USD | 19.84% |
| 2023 Q4 | -3.03 Million USD | 7.42% |
| 2023 Q3 | -3.27 Million USD | 22.77% |
| 2023 Q1 | -5.29 Million USD | -32.76% |
| 2023 FY | -15.84 Million USD | -13.97% |
| 2022 Q1 | -3.35 Million USD | 18.41% |
| 2022 Q3 | -3.54 Million USD | -17.81% |
| 2022 Q2 | -3.01 Million USD | 10.39% |
| 2022 FY | -13.9 Million USD | -33.11% |
| 2022 Q4 | -3.98 Million USD | -12.41% |
| 2021 Q3 | -2.06 Million USD | -14.37% |
| 2021 FY | -10.44 Million USD | 4.26% |
| 2021 Q1 | -2.44 Million USD | 4.04% |
| 2021 Q2 | -1.8 Million USD | 26.1% |
| 2021 Q4 | -4.11 Million USD | -98.99% |
| 2020 Q2 | -2.04 Million USD | 38.91% |
| 2020 FY | -10.9 Million USD | -25.48% |
| 2020 Q1 | -3.34 Million USD | -38.58% |
| 2020 Q4 | -2.55 Million USD | 14.11% |
| 2020 Q3 | -2.97 Million USD | -45.37% |
| 2019 Q4 | -2.41 Million USD | -6.25% |
| 2019 Q2 | -2.48 Million USD | -63.75% |
| 2019 Q3 | -2.27 Million USD | 8.76% |
| 2019 FY | -8.69 Million USD | -1.2% |
| 2019 Q1 | -1.52 Million USD | 20.42% |
| 2018 Q3 | -3.08 Million USD | -83.56% |
| 2018 FY | -8.59 Million USD | 4.19% |
| 2018 Q4 | -1.91 Million USD | 38.03% |
| 2018 Q2 | -1.67 Million USD | 12.51% |
| 2018 Q1 | -1.91 Million USD | 11.53% |
| 2017 Q2 | -2.32 Million USD | -16.48% |
| 2017 Q4 | -2.16 Million USD | 12.4% |
| 2017 FY | -8.96 Million USD | -5.79% |
| 2017 Q1 | -1.99 Million USD | -19.66% |
| 2017 Q3 | -2.47 Million USD | -6.49% |
| 2016 FY | -8.47 Million USD | -54.53% |
| 2016 Q1 | -1.86 Million USD | -27.82% |
| 2016 Q2 | -1.94 Million USD | -4.01% |
| 2016 Q3 | -2.99 Million USD | -54.01% |
| 2016 Q4 | -1.66 Million USD | 44.29% |
| 2015 Q3 | -1.51 Million USD | -33.73% |
| 2015 Q1 | -1.37 Million USD | 13.99% |
| 2015 FY | -5.48 Million USD | -20.74% |
| 2015 Q2 | -1.13 Million USD | 17.98% |
| 2015 Q4 | -1.46 Million USD | 3.32% |
| 2014 Q3 | -1.15 Million USD | 9.47% |
| 2014 Q1 | -510.21 Thousand USD | 35.49% |
| 2014 Q2 | -1.27 Million USD | -149.86% |
| 2014 FY | -4.54 Million USD | -38.94% |
| 2014 Q4 | -1.6 Million USD | -38.91% |
| 2013 Q3 | -1.39 Million USD | -225.15% |
| 2013 FY | -3.26 Million USD | -26.58% |
| 2013 Q4 | -790.95 Thousand USD | 43.25% |
| 2013 Q2 | -428.64 Thousand USD | 34.65% |
| 2013 Q1 | -655.91 Thousand USD | -51.91% |
| 2012 FY | -2.58 Million USD | -9.18% |
| 2012 Q2 | -787.78 Thousand USD | -50.74% |
| 2012 Q1 | -522.62 Thousand USD | 35.05% |
| 2012 Q4 | -431.78 Thousand USD | 48.63% |
| 2012 Q3 | -840.48 Thousand USD | -6.69% |
| 2011 FY | -2.36 Million USD | -1.68% |
| 2011 Q4 | -804.62 Thousand USD | -59.49% |
| 2011 Q3 | -504.48 Thousand USD | -8.78% |
| 2011 Q1 | -592.73 Thousand USD | 34.63% |
| 2011 Q2 | -463.76 Thousand USD | 21.76% |
| 2010 Q1 | -491.54 Thousand USD | -13.66% |
| 2010 Q3 | -501.28 Thousand USD | -17.44% |
| 2010 Q4 | -906.76 Thousand USD | -80.89% |
| 2010 FY | -2.32 Million USD | -17.91% |
| 2010 Q2 | -426.83 Thousand USD | 13.16% |
| 2009 Q3 | -407.05 Thousand USD | 23.71% |
| 2009 FY | -1.97 Million USD | 31.82% |
| 2009 Q4 | -432.47 Thousand USD | -6.25% |
| 2009 Q2 | -533.52 Thousand USD | 11.07% |
| 2009 Q1 | -599.92 Thousand USD | 68.33% |
| 2008 Q4 | -1.89 Million USD | -667.83% |
| 2008 Q2 | -508.73 Thousand USD | -108.59% |
| 2008 FY | -2.89 Million USD | -2552.14% |
| 2008 Q3 | -246.73 Thousand USD | 51.5% |
| 2008 Q1 | -243.89 Thousand USD | -14.77% |
| 2007 Q4 | -212.5 Thousand USD | -900.45% |
| 2007 FY | -109.11 Thousand USD | 19.34% |
| 2007 Q1 | -23.36 Thousand USD | 24.05% |
| 2007 Q2 | -26.33 Thousand USD | -12.71% |
| 2007 Q3 | -21.24 Thousand USD | 19.36% |
| 2006 Q1 | -20.32 Thousand USD | -48.38% |
| 2006 Q4 | -30.76 Thousand USD | -7.44% |
| 2006 Q3 | -28.63 Thousand USD | 64.35% |
| 2006 Q2 | -80.32 Thousand USD | -295.25% |
| 2006 FY | -135.26 Thousand USD | -102.04% |
| 2005 Q2 | -34.07 Thousand USD | -132.91% |
| 2005 Q3 | -20.92 Thousand USD | 38.6% |
| 2005 FY | -66.95 Thousand USD | -23.38% |
| 2005 Q4 | -13.69 Thousand USD | 34.53% |
| 2005 Q1 | -14.62 Thousand USD | -36.02% |
| 2004 Q3 | -7497.00 USD | 0.0% |
| 2004 FY | -54.26 Thousand USD | 0.0% |
| 2004 Q4 | -10.75 Thousand USD | -43.44% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -3115.913% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -66.453% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 47.178% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 76.404% |
| Better Therapeutics, Inc. | -38.26 Million USD | 58.593% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 62.345% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -32.356% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 53.188% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 53.97% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 85.394% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -686.526% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 53.406% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 66.256% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -1058.634% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 20.544% |
| Molecular Templates, Inc. | -10.46 Million USD | -51.376% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -12.754% |
| NexImmune, Inc. | -29.19 Million USD | 45.729% |
| Orgenesis Inc. | -53.63 Million USD | 70.462% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 69.113% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -20207.113% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 1.872% |
| Scopus BioPharma Inc. | -11.71 Million USD | -35.238% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 96.859% |
| Statera Biopharma, Inc. | -98.34 Million USD | 83.89% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -129.675% |
| Trevena, Inc. | -35.28 Million USD | 55.104% |
| Vaxxinity, Inc. | -58.28 Million USD | 72.818% |
| Vaccinex, Inc. | -22.88 Million USD | 30.771% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1413.212% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 68.747% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -118.133% |